BiotechTube

Temozolomide

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma

Conditions

Glioma

Trial Timeline

Jan 1, 2009 → Dec 1, 2010

NCT ID
NCT00660283

About Temozolomide

Temozolomide is a phase 2 stage product being developed by Eisai for Glioma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00660283. Target conditions include Glioma.

What happened to similar drugs?

0 of 3 similar drugs in Glioma were approved

Approved (0) Terminated (0) Active (3)
🔄Everolimus + ONC201Jazz PharmaceuticalsPhase 3
🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3
🔄safusidenib + PlaceboNuvation BioPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00660283Phase 2UNKNOWN

Competing Products

20 competing products in Glioma

See all competitors
ProductCompanyStageHype Score
TemozolomideNovocurePhase 1
15
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
29
LY2157299 + LomustineEli LillyPhase 1
29
DS-1001bDaiichi SankyoPhase 2
39
DS-1001bDaiichi SankyoPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
32
Temozolomide and BevacizumabEisaiPhase 2
31
Gliadel Wafer + TemozolomideEisaiPhase 2
31
Palonosetron (PALO)EisaiPhase 2
35
Gliadel/Avastin/CPT-11EisaiPhase 2
27
Lenvatinib + BevacizumabEisaiPhase 2
35
Granisetron + OndansetronKyowa KirinPhase 2
27
Binimetinib 15 MGOno PharmaceuticalPhase 2
42
EnzastaurinEli LillyPhase 2
35
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
32
Abemaciclib + TemozolomideEli LillyPhase 2
39
DSP-0390Sumitomo PharmaPhase 1
36
DSP-0390Sumitomo PharmaPhase 1
33
ApatinibJiangsu Hengrui MedicinePhase 2
31